undersigned authors wish to report the following. ''Despite repeated attempts, we have been unable to repeat the PRF-mediated transcriptional activation of the cMYC promoter by these viral oncoproteins as described in this paper. In contrast, our findings that vIRF (1-3) and EBNA2 (4) interact with p300 and CBP have been shown independently by others. We can no longer support our conclusion of specific viral oncoprotein activation of the cMYC promoter through the PRF element. We regret the confusion that this may have caused
The MYC protooncogene regulates cellular proliferation and is overexpressed in most tumors, including tumors caused by viruses. Interferons are antiinfective and antitumor cytokines that induce cell cycle arrest by repressing MYC transcription (1, 2) as well as activating transcription of tumor suppressor genes, such as the cyclin-dependent kinase inhibitor p21 gene (Cdkn1a) (3, 4) . Transcriptional regulation by interferon signaling is mediated through interferon regulatory factors (IRF), a family of transcription factors (5) that bind at specific interferon-stimulated response elements (ISREs) in promoters of interferon-regulated genes (6) .
Gene transactivation during interferon signaling (for example, the p21 gene) occurs by positively acting IRFs binding to ISRE. IRF1 in association with other transcription factors (7) cooperatively recruits transcription coadaptors, such as the p300, cAMP response element-binding protein (CREB)-binding protein (CBP), and p300͞CBP-associated factor (P͞ CAF) histone acetyltransferases (HATs) (8, 9) . HATs recruited by transcription factors acetylate core histones to relax DNA strands at transcription initiation sites and may serve as a scaffold for transcription complexes (for review, see ref. 10 ). p300 and CBP HAT coadaptors act at a wide variety of promoters but their activities are generally indistinguishable, and hence these factors are usually referred to together as p300͞CBP. Knockout mice and ribozyme inhibition studies show that p300 and CBP have distinct and noncompensatory activities (11, 12) , but they have not been found to antagonize each other. P͞CAF binds p300 and CBP and also has intrinsic HAT activity independent of other coadaptors.
Transcriptional repression by interferon signaling is less well understood. The MYC promoter contains an ISRE sequence (13) called the plasmacytoma repressor factor (PRF) element that binds IRF1 (unpublished observation), as well as the non-IRF transcriptional repressor BLIMP-1͞PRDI-BF1 responsible for terminal B cell differentiation (14) . While IRF1 transactivates most interferon-regulated promoters such as the p21 promoter, it effectively represses MYC transcription through the PRF element (unpublished observation), accounting for MYC down-regulation occurring after interferon treatment (1, 2) .
Inhibiting HAT coactivation is an effective viral strategy to escape antiviral effects of interferon signaling. Adenovirus E1A transforming protein binds p300, CBP (15) , and P͞CAF (16) , inhibiting their activity in interferon-related transcription (17, 18) . Coadaptor binding by E1A is required for cell transformation (30) . Kaposi sarcoma-associated herpesvirus (KSHV) viral IRF (vIRF) protein also inhibits interferonmediated transcription, but its mechanism is unknown (19) (20) (21) (22) . vIRF prevents interferon-induced cell cycle arrest in Daudi cells (20) , inhibits p21 up-regulation by interferon (19, 21) , and fully transforms NIH 3T3 cells (19, 21) . Although vIRF has homology to cellular IRFs, it does not directly bind ISRE DNA sequences. Similarly, the unrelated Epstein-Barr virus (EBV)-induced nuclear antigen 2 (EBNA2) transforming protein also inhibits interferon-mediated transcription but
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does not bind DNA (23) . Recent studies demonstrate that EBNA2 directly activates MYC, but the site of activation and DNA-binding copartner protein have not been described (24) .
In this study, we show that vIRF, EBNA2, and E1A share the common property of transactivating MYC through the PRF element. This activation is related to their ability to interact with different sets of transcription coadaptors. These findings suggest convergent evolution among some tumor viruses to activate the MYC protooncogene as a response to innate immune mechanisms.
MATERIALS AND METHODS
Cell Lines. 18-81 cells, a gift from K. Calame (Columbia Univ.), were maintained in RPMI medium 1640 with 10% fetal calf serum (FCS) and 50 mM 2-mercaptoethanol. IRF1͞2Ϫ͞Ϫ mouse embryo fibroblasts (MEF), a gift from T. Taniguchi and J. Sample (25) , were maintained in DMEM with 10% FCS. Derivative NIH 3T3 cell lines (C2, C7, and C0) have been previously reported (19) and were selected for stable transfection of pBpuroMyc D106-143MER with 500 g͞ml G418 and 5 g͞ml puromycin. Soft agar and cell doubling assays were performed as previously described (19) .
Plasmids. pBB-Luc, p⌬PRFBB-Luc, pBpuroMyc D106-143MER, and the BLIMP-1 expression construct were provided by K. Calame (14, 26, 27) , and human MYC promoter luciferase reporter Del-1 was a gift of K. Kinzler (Johns Hopkins Oncology Center) (28) . KSHV pvIRF and EBV EBNA2 (strain B95-8) pPDL151 expression plasmids, the pPDL152 plasmid expressing EBNA2 ⌬CBF , and the EBV C promoter reporter plasmids pDL84A have been previously described (19, 29) . HES-1-Luc and HES-1 AmB-Luc promoter reporters were gifts from G. Siu (Columbia Univ.). p12S-WT expressing adenovirus 12S E1A and p12S(⌬2-36) expressing E1A ⌬2-36 were gifts from E. Moran (Temple Univ.) (30) , and pCMV␤-p300 was a gift from D. Livingston (Harvard Univ.). p300 deletion constructs were derived from the parent plasmid by cloning to pcDNA3.1HisC after digestion using SphI, BamHI, SacI, and BstXI, corresponding to p300 , p300 , p300 , and p300 respectively (detailed cloning strategies available on request). The 4-hydroxytamoxifen (4HT)-activated pvIRF-ER fusion plasmid was derived from pBpuroMyc D106-143MER by PCR cloning KSHV ORF K9 inframe with the modified estrogen receptor gene. The pPRDII 4 -Luc reporter, pDNIRF, pp65, pRSV-CBP, pRSV-CBP F3 A (constructed by mutagenesis of Phe-1541 to Ala) and pCX-Flag-P͞CAF (31) expression plasmids were gifts from D. Thanos (Columbia Univ.) (7) . pcDNAHis3.1LacZ (Invitrogen) was used to normalize luciferase activity to transfection efficiency.
Promoter Reporter Assays. Cells were seeded at a density of 5 ϫ 10 4 cells per plate in six-well plates 1 day before transfection to ensure exponential-phase growth at harvesting, since the cMYC promoter is cell cycle regulated. Transient transfections with plasmid DNA were performed using Cell Phect (Pharmacia Biotech). In all experiments, total amounts of transfected DNA were equalized between wells by using empty pcDNA3.1 His C (Invitrogen). Cells were harvested and lysed, and luciferase activity was measured by using standard protocols after 48 hr. Luciferase activity was normalized by ␤-galactosidase activity. Each measurement was performed in triplicate, with most experiments independently replicated at least three times. Data are the average values for all experiments (normalized to transfection with reporter alone); error bars represent standard errors of the mean.
Inhibition by Cycloheximide. IRF1͞2Ϫ͞Ϫ cells were transfected with 2 g of pBB-Luc or pBB-Luc and 1 g of pvIRF-ER. Two days after transfection cells were treated with 100 g͞ml cycloheximide for 1 1 ⁄2 hr, then 100 nM 4HT was added. Northern blotting was performed on equal amounts of poly(A)-selected mRNA (1 g per well) from 2.5 ϫ 10 5 treated and untreated control cells on 1% agarose͞formaldehyde gels as previously described (32) . For detection of luciferase mRNA, a 1.6-kb NcoI-XbaI fragment from pGL3-Basic (Promega) was random prime labeled by using Redi-prime II (Amersham Pharmacia Biotech). Equivalent loading was confirmed by using a mouse ␤-actin probe (not shown).
Immunoblotting, Coimmunoprecipitation, and Glutathione S-Transferase (GST)-Pull-Down Assays. vIRF (5 g of pvIRF), EBNA2 (5 g of pPDL151), or EBNA2 ⌬CBF (5 g of pPDL152) was expressed together with p300 (5 g of pCMV␤-300) in IRF1͞2Ϫ͞Ϫ cells by cotransfection, and complexed proteins were immunoprecipitated with an N-terminal p300 antibody (N-15, Santa Cruz Biotechnology). Protein complexes were resolved by SDS͞12.5% PAGE and transferred onto nitrocellulose membranes. vIRF was detected by using specific polyclonal antibodies (R442-R443, 1:1000), and EBNA2͞EBNA2 ⌬CBF were detected by using a monoclonal antibody (clone PE-2, 1:1000, Dako) by immunoblotting and enhanced chemiluminescence (ECL, Amersham). For detection of cMYC protein, N-262 and C-19 antibodies (Santa Cruz Biotechnology) were used. GST binding assays were performed with in vitro translated [ 35 S]methionine-labeled vIRF (TNT reticulocyte lysates; Promega).
RESULTS cMYC Protein Expression Is Required for vIRF-Mediated Cell
Transformation. We investigated the mechanism for vIRF's effect on cell proliferation by examining cMYC protein expression in two previously derived, vIRF-transformed NIH 3T3 clones, C2 and C7 (19) . Both clones express higher levels of cMYC protein during exponential growth than does the C0 clone stably transfected with empty pcDNA vector alone (Fig. 1A) . To determine whether vIRF transformation is reversed by cMYC inhibition, all three clones were puromycin-selected for expression of an inducible dominant-negative cMYC (DNMYC) estrogen receptor fusion protein which translocates to the nucleus in response to 4HT (27) . After addition of 4HT, doubling times for C2 DNMYC and C7 DNMYC cells increased from 24 hr to 120 hr, and colony formation on soft agar was markedly reduced (Fig. 1B) . Trypan blue vital staining demonstrated that this effect is not due to 4HT toxicity (not shown). Thus, active cMYC is required for cell transformation and MYC induction is downstream from vIRF in the transformation pathway as is the case for E1A (55) .
KSHV vIRF Transactivates MYC Promoter Through the PRF Element. Direct evidence for MYC promoter activation by vIRF was found by using the pBB-Luc plasmid, in which the mouse MYC promoter regulates expression of a luciferase reporter gene (26) . vIRF expression induces MYC promoter in a dose-dependent fashion in 18-81 murine pre-B cells lacking endogenous BLIMP-1 (Fig. 1C) . MYC promoter is also activated by vIRF in a highly transfectable mouse embryonic fibroblast cell line null for the IRF1 and IRF2 transcription factors (IRF1͞2Ϫ͞Ϫ) (Fig. 1C ) and in NIH 3T3 cells (not shown). vIRF does not activate a mutant promoter reporter (p⌬PRFBB-Luc) lacking the PRF element, whereas YY1 transactivates both pBB-Luc and p⌬PRFBB-Luc (33) . vIRF also transactivates the human MYC Del1 promoter-reporter (28) containing a PRF element (not shown). Nonspecific activation does not occur when vIRF is expressed with the pGL3 control reporter. vIRF does not directly bind PRF DNA in either electrophoretic mobility-shift assays or DNA footprinting experiments (not shown), consistent with the previously reported inability of vIRF to bind ISRE sequences (19) (20) (21) (22) 1D) . A 4HT-responsive, vIRF-estrogen receptor fusion protein was fully active in inducing MYC after 4HT treatment (not shown). This expression plasmid was transiently transfected with the pBB-Luc reporter into IRF1͞2Ϫ͞Ϫ cells, and luciferase mRNA expression was measured by Northern blotting. Cycloheximide pretreatment does not prevent transactivation of pBB-Luc by preformed vIRF-ER fusion protein after 4HT treatment (Fig. 1D, lane 6) . Therefore, vIRF transactivation of MYC does not require de novo protein synthesis and acts directly at the MYC promoter as EBNA2 does (24) . Because vIRF does not bind the PRF element, it appears to interact with an unidentified ISRE enhancer binding factor (IEB), which is likely to be one of eight known ISRE-binding proteins (34) . IEB is not IRF1, IRF2, or BLIMP-1 because these factors are not expressed in IRF1͞2Ϫ͞Ϫ and 18-81 cells, respectively. Rigorous identification of IEB requires knocking out the remaining factors or examining cell lines lacking individual factors. Determining the mechanism by which this viral transforming protein transactivates MYC was approached by using DN-IRF. DN-IRF has the IRF-1 DNA-binding domain, which competes for ISRE-binding, but lacks an activation domain (7) . If vIRF binds IEB to form an active transcription factor recognizing PRF, DN-IRF should compete with IEB and thus inhibit vIRF induction of MYC (Fig.  1E, model 1) . If IEB is a MYC repressor (like BLIMP-1) which is inactivated by vIRF, then DN-IRF should also activate MYC (Fig. 1E, model 2) . DN-IRF does not activate pBB-Luc but instead antagonizes vIRF, which is consistent with vIRF and IEB acting together as a transactivator.
CBP Synergistically Coactivates, Whereas p300 and P͞CAF Suppress, vIRF Transactivation of MYC. To determine whether vIRF interacts with other components of the transcriptional complex, we examined the transcription coadaptors p300 and CBP. p300 coimmunoprecipitates vIRF from cell extracts when both proteins are expressed together ( Fig. 2A) . Immunoprecipitating successive p300 truncation proteins localized the vIRF-binding site to a region that includes amino acids 596-744 between the CREB and C͞H2 domains. This localization was confirmed by in vitro GST-pull-down assays in which GST-p300 fusion proteins possessing amino acids 596-744 precipitated [ 35 S]methionine-labeled vIRF, whereas proteins truncated shorter than amino acid 596 did not (Fig. 2B) . As anticipated by sequence similarity, full-length CBP also coimmunoprecipitates vIRF in vivo, demonstrating specific vIRF interaction with both coadaptors (not shown).
Unexpectedly, CBP and p300 have opposing effects on vIRF transactivation of MYC. To first test for CBP and p300 coactivator activity in a model system, the interferon-␤ pPR-DII 4 -Luc promoter reporter containing four NF-B binding sites was examined (Fig. 3A) . As previously described by others (7, 35, 36) , both CBP and p300 synergistically coactivate NF-B p65 transactivation of the PRDII element, whereas a mutant CBP (CBP F3A ) with a single substitution mutation in the HAT domain is completely inactive. For the pBB-Luc promoter reporter, however, only CBP synergistically coactivates, while p300, CBP F3A , and P͞CAF markedly inhibit vIRF transactivation in a monotonic dose-dependent fashion (Fig.  3B ). To our knowledge, this is the first evidence of opposite activities for CBP and p300. This result is not due to transcriptional squelching resulting from free transactivator titrating away components of the transcriptional complex (37) . Instead, this appears to be a novel means of gene regulation in which two highly homologous coadaptors, one active (CBP) and the other inactive (p300), compete with each other for a transcription factor (vIRF) at the MYC promoter (Fig. 3C) . We call this effect ''coadaptor quenching,'' and it is the obverse of nuclear receptor and AP1 transcription factor competition for p300͞CBP (38) .
E1A and EBNA2 also Activate MYC Through the PRF Element by Using Different Coadaptors. We examined the unrelated E1A and EBNA2 viral transforming proteins because of their interferon inhibition and MYC activation activities. E1A not only binds to CBP, p300, and P͞CAF through an amino-terminal interaction domain (16) , it competes with P͞CAF for CBP binding (31) . EBNA2, however, has not been previously shown to interact with transcription coadaptors.
Like vIRF, these viral proteins also interact with CBP͞p300 family coadaptors and transactivate MYC through the PRF element. EBNA2 coimmunoprecipitates with p300 in vivo, when we use B95-8 EBNA2 and EBNA2 ⌬CBF , which does not bind RBP-Jk͞CBF-1 (39-41), a transcription factor activated by EBNA2 (Fig. 4A) . EBNA2 binds to p300 in a region bracketed by the C͞H1 and CREB domains (amino acids 347-596), and full-length CBP also coimmunoprecipitates EBNA2 in vivo (not shown).
Both EBNA2 and E1A also activate pBB-Luc but not ⌬PRFBB-Luc (Fig. 4B) . Importantly, E1A induction is absent in an amino-terminal mutant (E1A ⌬2-36 ) that does not bind p300͞CBP (30) . The EBNA2 ⌬CBF protein also transactivates pBB-Luc, indicating this effect is independent of RPB-Jk͞ CBF1 activation (Fig. 4B) , and vIRF does not activate EBV C or HES-1-Luc reporters that are activated by RPB-Jk͞CBF1 (data not shown). The HTLV I Tax protein, which also binds CBP͞p300 (42) but induces MYC promoter through direct NF-B activation (43) , has equal activity on pBB-Luc and p⌬PRFBB-Luc reporters, which have intact NF-B elements.
MYC activation by E1A and EBNA2 is related to coadaptor interaction. EBNA2 in the presence of increasing amounts of CBP (up to 1 g of plasmid) results in 16-fold pBB-Luc activation, whereas p300 overexpression results in complete suppression of EBNA2 transactivation (Fig. 4C) . Unlike vIRF, EBNA2 is coactivated up to 10-fold by P͞CAF. Both CBP and P͞CAF squelch pBB-Luc transcription at high doses of expression plasmid. E1A demonstrates yet another pattern: P͞CAF alone (up to 100 ng) is a coactivator, whereas CBP and p300 effectively suppress E1A transactivation of MYC (Fig.  4D) . Repression by p300 appears to be due to a competitive mechanism, rather than a noncompetitive mechanism such as acetylation of transcriptional complex components, in that increasing amounts of CBP reverse p300 inhibition of vIRF and EBNA2 transactivation of MYC (Fig. 4E) .
Because P͞CAF itself binds CBP͞p300, combinations of coadaptor expression plasmids were examined (Fig. 4F) . No increased transactivation occurred for either EBNA2 or E1A when P͞CAF was coexpressed with CBP (not shown) or p300 (1 g each) compared with P͞CAF expression alone. Like CBP coexpression with vIRF, P͞CAF coexpression reverses the inhibitory effect of p300 on E1A and EBNA2 in a dosedependent manner (Fig. 4G) , consistent with a competitive mechanism. In contrast, E1A ⌬2-36 does not activate MYC in the presence of P͞CAF, indicating that this deletion also functionally interferes with the P͞CAF coactivation of MYC (not shown). 
DISCUSSION
Several tumor viruses have independently evolved the ability to inhibit interferon-related signaling (19) (20) (21) (22) (23) 44) . vIRF, EBNA2, and E1A not only prevent interferon activation of interferon-stimulated genes but also transactivate at least one gene (MYC) generally repressed by interferon signaling. Because cMYC regulates mitogenesis resulting in S-phase entry, MYC down-regulation by interferon could be an innate immune response to limit viral nucleic acid synthesis, thus becoming an important viral target. The viral proteins in this study do not specifically recognize the PRF DNA sequence, and therefore transactivation of MYC requires a cellular partner, IEB. It is not known whether IEB is the same protein for all three viral transforming proteins.
Transactivation of MYC may contribute to cell transformation by some tumor viruses, but it is only one of multiple processes leading to uncontrolled cell proliferation. Several cellular pathways are independently targeted by most if not all direct viral carcinogens. Most prominently, tumor viruses generally encode proteins to inactivate both RB1 and p53 tumor suppressor pathways (45) (46) (47) (48) (49) (50) (51) (52) . MYC transactivation may be another common target for tumor virus transforming proteins, but not all tumor viruses use the PRF element to achieve this. HTLV-I Tax protein, for example, increases MYC transcription but does so through NF-B sites rather than the PRF element (43) . Since interferons are mitogenic and induce MYC in T cells (53) , the natural host cell for HTLV-I, inhibition of interferon signaling might be counterproductive for T cell trophic viruses in maintaining an active cell cycle. Further, E1A and EBNA2 are multifunctional proteins affecting other regulatory pathways such as RB1 (47) and RBP-Jk͞ CBF1 (39-41) independent of their MYC activation activities.
Each viral transforming protein has a different profile for coadaptor usage at the PRF element, as shown in Table 1 . A surprising result from our study is that p300 and CBP have not only different activities at the MYC promoter but also opposing effects. This clearly differs from their activities at other promoters, and several lines of evidence suggest that quenching occurs through a competitive mechanism in a promoterspecific context. Mutant CBP lacking HAT activity is not neutral but instead suppresses vIRF transactivation, an effect not seen with p65 on the PRDII promoter-reporter. Both CBP and P͞CAF also can competitively reverse the inhibitory effects of p300, indicating that repression by p300 is not due to acetylation of components of the transcription complex. Further, in vitro acetylation studies indicate that the viral transforming proteins are not acetylation targets for either CBP or p300 (data not shown). If coadaptor quenching occurs with cellular transcription factors under in vivo conditions (as well as viral transcription factors under the artificial promoter conditions used here), this could provide flexible gene regulation. This would be the case for signaling pathways, such as the interferon signaling pathway, that simultaneously activate some promoters while suppressing others without recruitment of specific repressor molecules (e.g., HATs). vIRF is primarily expressed in Castleman's disease, a severe KSHV-related lymphoproliferative disorder, but not Kaposi sarcoma or primary effusion lymphoma (supplemental data: http:͞͞patholog y.cpmc.columbia.edu͞CMLA B.html). EBNA2 expression also primarily occurs in EBV-related B cell lymphoproliferative disorders, suggesting that abrogation of interferon repression of MYC may be of principal importance in B cell proliferative disorders. vIRF is a class II transcript in vitro (32) and its expression is increased during lytic replication. While vIRF transforms fibroblasts in vitro, this does not necessarily imply a role for vIRF in KSHV-related tumorigenesis. The importance of our study, however, is that it demonstrates that a major protooncogene is repressed by innate immune responses and that diverse viruses target this pathway as a means to enhance viral survival and replication. This previously undescribed link between innate immune responses and the MYC protooncogene is consistent with the hypothesis that some tumor suppressor pathways have dual antiviral activities, and viral oncoproteins targeting these pathways may inadvertently result in cell transformation (54) . The importance of this effect is demonstrated from the convergent evolution by different tumor viruses to target the PRF regulatory site through coadaptor interactions.
